<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of hyperglycemia in patients with type 2 diabetes and advanced chronic kidney disease or end-stage kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel D Glickman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony DeSantis, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) is associated with insulin resistance, and in patients with diabetes, glycemic control may deteriorate as kidney function declines. In advanced CKD, however, there is a marked reduction in insulin clearance, leading to a decrease in insulin requirement or even the cessation of insulin therapy in patients with type 2 diabetes. Because of the uncertainty in predicting diabetes medication requirements, an individualized approach is essential for patients who have advanced CKD or are initiating dialysis.</p><p>This topic reviews monitoring glycemic control, glycemic targets, and suggested treatment regimens for patients with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup> who are not on dialysis as well as for patients on hemodialysis or peritoneal dialysis. The treatment of hyperglycemia in patients with mildly to moderately decreased eGFR (30 to 59 mL/min/1.73 m<sup>2</sup>) and in kidney transplant recipients is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus", section on 'Management of hyperglycemia in the first 6 weeks after transplantation'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus", section on 'Management of PTDM'</a>.)</p><p></p><p class="headingAnchor" id="H109015232"><span class="h1">MONITORING GLYCEMIA</span></p><p class="headingAnchor" id="H109015808"><span class="h2">Chronic glycemia</span><span class="headingEndMark"> — </span>Measures of chronic glycemia (eg, glycated hemoglobin) are used to determine the overall efficacy of diabetes management with the aim of reducing risk for long-term complications:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycated hemoglobin (A1C)</strong> – We assess chronic glycemic control in patients with diabetes and predialysis chronic kidney disease (CKD) or end-stage kidney disease (ESKD) with glycated hemoglobin (hemoglobin A1C, A1C) as we do in patients with diabetes and normal kidney function. When there is a disparity between the A1C values and blood glucose values, we rely on the glucose values; either glucose monitoring with fingersticks and a glucose meter or continuous glucose monitoring (CGM) may be used. (See  <a class="medical medical_review" href="/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus", section on 'Unexpected or discordant values'</a> and  <a class="medical medical_review" href="/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus", section on 'CGM to estimate average glucose'</a>.)</p><p></p><p class="bulletIndent1">The linear relationship between average glucose and A1C is similar in patients with and without CKD, although the relationship is weaker with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup> [<a href="#rid1">1</a>]. Most of the inaccuracy in the relationship between A1C and mean blood glucose in the setting of advanced CKD and hemodialysis is due to altered red cell turnover, especially in the setting of treatment with erythropoiesis-stimulating agents (ESAs). Rapid red cell turnover leads to a greater proportion of younger red cells and falsely low A1C values.</p><p></p><p class="bulletIndent1">In some older A1C assays, there was analytical interference from carbamylated hemoglobin (formed in the presence of elevated concentrations of urea), leading to false elevations in the A1C level. This is no longer a problem with most A1C assays [<a href="#rid2">2</a>]. It is important to be aware of the specific assay used in each dialysis facility and the extent to which kidney disease and other factors affect the accuracy of A1C measurements. Laboratories should only use A1C assay methods certified by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fngsp.org%2Fcertified.asp&amp;token=OKZ2BMoMnrH9FFn0ZVsAuKJP%2Fy9ogEPhboWJPBci8R9w%2FdOAOQdomY6w1FAk1qB2&amp;TOPIC_ID=1857" target="_blank">NGSP</a>. (See  <a class="medical medical_review" href="/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus", section on 'Standardization of the assay'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycated albumin</strong> – Some reports suggest that measurement of glycated albumin more accurately assesses glycemic control in this population [<a href="#rid3">3-6</a>]. Although glycated albumin also reflects mean glycemia, it reflects glycemic control over a much shorter interval (7 to 14 days, compared with 60 to 120 days for A1C). Glycated albumin measurements may not be reliable in patients with proteinuria or in those on peritoneal dialysis. In addition, in a small study in patients with type 2 diabetes and CKD undergoing intravenous iron or ESA therapy, A1C (compared with glycated albumin and other markers of glycemic control) was most closely associated with mean blood glucose [<a href="#rid7">7</a>]. There are few long-term clinical trials evaluating the relationship between glycated albumin and risk of chronic complications of diabetes [<a href="#rid8">8-10</a>]. For these reasons, we prefer monitoring glycemic control with A1C. (See  <a class="medical medical_review" href="/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus", section on 'Glycated hemoglobin (A1C)'</a>.)</p><p></p><p class="headingAnchor" id="H109015815"><span class="h2">Daily glucose measurements</span><span class="headingEndMark"> — </span>Measurements of instantaneous glucose levels (self-monitoring of blood glucose [with fingersticks and a glucose meter] and real-time CGM) are used to manage diabetes from hour-to-hour and day-to-day, to aid in dose selection in insulin-treated patients, and for safety.</p><p>All patients with diabetes mellitus who use insulin and some patients who take other glucose-lowering medications that can cause hypoglycemia should measure their blood glucose concentrations to help maintain safe, target-driven glucose control. The effectiveness of self-monitoring in patients with type 2 diabetes who do not use hypoglycemic agents is less certain. The indications for and practical points about blood glucose monitoring, including CGM, are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus"</a>.)</p><p>There are no long-term outcome data for patients on dialysis using CGM. A small study in patients on hemodialysis reported more frequent treatment changes, better glycemic control, and no increased risk of hypoglycemia [<a href="#rid11">11</a>]. Glucose metrics available through use of CGM, particularly time (percent) in target range (70 to 180 mg/dL), might support treatment decisions for individual patients who have A1C values discordant with self-monitored blood glucose measures or clinical symptoms. In addition, CGM can be particularly helpful when initiating new anti-hyperglycemic therapy or adjusting current medications to ensure achievement of glycemic targets and avoidance of hypoglycemia.</p><p>Of particular importance to patients receiving peritoneal dialysis is the finding that some glucose monitors (those using the enzyme glucose dehydrogenase pyrroloquinoline quinone) will give falsely elevated readings in patients who have received treatments containing other sugars, including <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> in peritoneal dialysis fluids [<a href="#rid12">12</a>]. This effect can persist for two weeks after stopping icodextrin (see  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions"</a>). New test strips have been designed to minimize interference with nonglucose sugars [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H317395202"><span class="h1">GLYCEMIC TARGETS</span><span class="headingEndMark"> — </span>The glycated hemoglobin (A1C) target that is associated with the best outcome in patients with chronic kidney disease (CKD) has not been established. Clinical practice guidelines recommend an individualized A1C target ranging from &lt;6.5 to &lt;8 percent, depending upon patient factors, such as risk of hypoglycemia, presence of cardiovascular disease, and life expectancy [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients not on dialysis (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m</strong><strong><sup>2</sup></strong><strong>)</strong> – For most patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who are not on dialysis, we suggest using an A1C target of approximately 7 percent, although the risks and benefits of targeting this goal are uncertain. Data supporting this goal are from studies of patients without CKD and are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on dialysis </strong>– For patients who are on dialysis, we individualize the A1C goal based upon the risk of hypoglycemia and presence of comorbid conditions. For patients who are relatively young (&lt;50 years) and without significant comorbid conditions, we suggest an A1C goal that is close to 7 percent (eg, 6.5 to 7.5). However, among older patients with multiple comorbid conditions, the A1C goal is closer to 8 percent (eg, 7.5 to 8).</p><p></p><p class="bulletIndent1">Although benefits associated with better glycemic control in patients on dialysis have been reported in several small observational studies [<a href="#rid16">16-18</a>], other larger observational studies have found no significant correlation between tight glycemic control and survival [<a href="#rid19">19-23</a>]. In a meta-analysis of observational studies of patients on hemodialysis, compared with A1C values of 6.5 to 7.4 percent, baseline (hazard ratio [HR] 1.14, 95% CI 1.09-1.19) and mean (HR 1.29, 95% CI 1.23-1.35) A1C values ≥8.5 percent were associated with an increase in mortality [<a href="#rid24">24</a>]. Among patients recently initiating hemodialysis, there was an increase in mortality associated with A1C values ≤5.4 percent. Such observational studies cannot establish a causal relationship between A1C levels and outcomes.</p><p></p><p class="headingAnchor" id="H109015354"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1045099710"><span class="h2">General management</span><span class="headingEndMark"> — </span>All patients with diabetes should participate in a comprehensive diabetes self-management education program, which includes individualized instruction on nutrition, physical activity, optimizing metabolic control, and preventing complications. For patients with type 2 diabetes, the majority of whom have overweight (body mass index [BMI] ≥25 to 29.9 kg/m<sup>2</sup>) or obesity (BMI ≥30 kg/m<sup>2</sup>), major emphasis should be placed on reducing caloric intake, increasing physical activity, and behavior modification to achieve weight loss. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Diabetes education'</a>.)</p><p>The additional burden of chronic kidney disease (CKD) dietary requirements (such as salt, protein, and volume restrictions) may further complicate diets in patients with diabetes. (See  <a class="medical medical_review" href="/d/html/1766.html" rel="external">"Nutritional considerations in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H1059286685"><span class="h2">Approach to pharmacologic therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapies for the treatment of hyperglycemia include oral agents, noninsulin injectable agents, and insulin. Although <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is the most commonly used drug to treat type 2 diabetes, it should not be used in patients with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup> because of an increased risk of lactic acidosis. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are being used increasingly to slow the progression of kidney disease in diabetes. They are relatively weak glucose-lowering medications and have reduced glycemic efficacy in individuals with an eGFR &lt;30 to 45 mL/min/1.73 m<sup>2</sup>, with some differences in each medication depending on the labeling. In this setting, additional agents may be necessary to achieve glycemic goals; nonetheless, an SGLT2 inhibitor may be initiated for kidney protection in individuals with an eGFR as low as 20 mL/min/1.73 m<sup>2</sup> [<a href="#rid15">15</a>]. (See <a class="local">'Medications not recommended for hyperglycemia'</a> below and  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.)</p><p>Our approach, which is largely in agreement with guidelines from the American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO), is described below  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>) [<a href="#rid14">14,15,25</a>].</p><p class="headingAnchor" id="H1901870915"><span class="h3">Patients not on dialysis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD stage 4</strong> – In patients with CKD stage 4, we suggest a glucagon-like peptide 1 (GLP-1) receptor agonist rather than another agent for glucose lowering  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>). The GLP-1 receptor agonists <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>, <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, and <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> have kidney and cardiovascular protective benefits as well as documented safety in patients with an eGFR &gt;15 mL/min/1.73 m<sup>2</sup> [<a href="#rid26">26-30</a>]. GLP-1 receptor agonists should be titrated slowly, monitoring for gastrointestinal side effects, which could precipitate dehydration and acute kidney injury (AKI). Sulfonylureas with the lowest risk of hypoglycemia (<a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, or <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a> [not available in the United States], <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a>, or <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>) are alternatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD stage 5</strong> – In patients with CKD stage 5 who are not on dialysis, we suggest a sulfonylurea with inactive metabolites and a relatively lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, or <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a> [not available in the United States]) rather than another agent  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">Repaglinide</a>, <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, or cautious use of a GLP-1 receptor agonist are alternatives to sulfonylureas with inactive metabolites. The choice of agent depends upon glycemic goals (see <a class="local">'Glycemic targets'</a> above); the risk of medication-associated adverse events (hypoglycemia, lactic acidosis); patient comorbidities and preferences; and convenience.</p><p></p><p>Patients who are unable to achieve their glycemic target with oral agents or a GLP-1 receptor agonist are treated with insulin. The indications for initiating insulin therapy and the principles underlying insulin therapy are the same for patients with nondialysis CKD as for the general diabetic population. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GLP-1 receptor agonists</strong> – GLP-1 receptor agonists stimulate glucose-dependent insulin secretion, suppress glucagon levels, delay gastric emptying, and increase satiety. Experience with GLP-1 agonists in patients with reduced kidney function is limited [<a href="#rid31">31-37</a>], and therefore, these agents should be used with caution. They should not be used in combination with dipeptidyl peptidase 4 (DPP-4) inhibitors.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">Liraglutide</a>, <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>, and <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a> (injection) have demonstrated cardiorenal benefit in patients with type 2 diabetes and cardiorenal disease, including a minority of patients with an eGFR between 15 to 30 mL/min/1.73 m<sup>2</sup> [<a href="#rid26">26-30</a>]. They are not excreted by the kidneys, and dose reductions with impaired kidney function are not necessary [<a href="#rid38">38</a>]. They may be used in CKD stage 4, but patient education for signs and symptoms of dehydration due to nausea or satiety is warranted to reduce the risk of AKI [<a href="#rid38">38,39</a>]. Dulaglutide should not be used in patients with an eGFR ≤15 mL/min/1.73 m<sup>2</sup>. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Microvascular outcomes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfonylureas</strong> – Sulfonylureas with the lowest risk of hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> or <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>) are reasonable agents for patients who have an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> [<a href="#rid31">31-33,37,40</a>]. <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">Gliclazide</a> is a similar agent that is not available in the United States. <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">Glyburide</a> (also known as glibenclamide) and other long-acting sulfonylureas are generally not recommended in any patient with type 2 diabetes because of the risk of hypoglycemia. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">The sulfonylureas are strongly protein bound, particularly to albumin. Thus, elevated plasma drug levels cannot be efficiently reversed by hemodialysis. Furthermore, displacement of these drugs from albumin by beta blockers, salicylates, and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> can lead to hypoglycemia due to increased plasma concentration of the free sulfonylurea.</p><p></p><p class="bulletIndent1">The administration of sulfonylureas in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who are not on dialysis requires careful attention to dosing and routes of elimination [<a href="#rid31">31-34</a>]. Treatment should be initiated with low doses that can be titrated upward as needed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glipizide</strong> – The initial dose is 2.5 mg/day taken 30 minutes before breakfast. <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">Glipizide</a> is a short-acting agent that is metabolized by the liver and primarily excreted in the urine as inactive metabolites.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glimepiride</strong> – The initial dose is 1 mg/day with breakfast. <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">Glimepiride</a> is primarily metabolized by the liver, with renal excretion of at least one active metabolite. It can be used at low doses in patients with CKD but should be avoided in patients with end-stage kidney disease (ESKD) because of a risk of prolonged hypoglycemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gliclazide</strong> (not available in the United States) – The initial dose is 40 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repaglinide</strong> – Some clinicians use <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> (a meglitinide) for patients not on dialysis since it is not cleared by the kidneys. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">Repaglinide</a> acts at the sulfonylurea receptor to increase insulin secretion but is much shorter acting than sulfonylureas and is principally metabolized by the liver, with less than 10 percent renally excreted [<a href="#rid31">31-34</a>].</p><p></p><p class="bulletIndent1">In patients with an eGFR &lt;40 mL/min/1.73 m<sup>2</sup>, initiation of <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> should be with 0.5 mg before the largest meal and then advanced to 0.5 mg prior to other meals, as needed. Repaglinide has not been studied in patients with an eGFR &lt;20 mL/min/1.73 m<sup>2</sup>. (See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Dosing and monitoring'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9927" href="/d/drug information/9927.html" rel="external">Nateglinide</a> (another meglitinide) is hepatically metabolized, with renal excretion of active metabolites. With decreased kidney function, these metabolites can accumulate and cause hypoglycemia [<a href="#rid31">31,32,34</a>]. This drug should therefore be avoided in patients with advanced CKD or ESKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DPP-4 inhibitors</strong> – Limited data suggest that DPP-4 inhibitors (eg, <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>, <a class="drug drug_general" data-topicid="9534" href="/d/drug information/9534.html" rel="external">saxagliptin</a>) are effective and relatively safe in patients with CKD [<a href="#rid32">32-34,37</a>]. Linagliptin is only minimally excreted in the urine (&lt;10 percent), and it is the only DPP-4 inhibitor that does not require a dose (5 mg once daily) adjustment in the setting of kidney failure [<a href="#rid41">41,42</a>]. (See  <a class="medical medical_review" href="/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus", section on 'Efficacy in chronic kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">Sitagliptin</a> is largely excreted in the urine, with 70 to 80 percent of an oral dose appearing unchanged in the urine [<a href="#rid43">43</a>]. If sitagliptin is used among patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, a dose reduction to 25 mg daily (usual dose 100 mg daily) is recommended.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9534" href="/d/drug information/9534.html" rel="external">Saxagliptin</a> and its primary active metabolite are excreted in the urine (total urinary excretion approximately 60 to 75 percent); a daily dose of 2.5 mg is the recommended dose for patients with an eGFR &lt;45 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1">Experience with other drugs of this class in patients with CKD or ESKD is limited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin</strong> – Among patients who are treated with insulin, the starting dose of insulin may need to be lower than would ordinarily be used for patients with normal kidney function. CKD is associated with decreased kidney and ultimately hepatic metabolism of insulin (see  <a class="medical medical_review" href="/d/html/1974.html" rel="external">"Carbohydrate and insulin metabolism in chronic kidney disease"</a>). As a result, the following dose recommendations have been made for insulin dosing in this setting if the patient is reaching his or her glycemic target [<a href="#rid44">44-46</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No dose adjustment is required if the eGFR is &gt;50 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The insulin dose should be reduced to approximately 75 percent of baseline when the eGFR is between 10 and 50 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The dose should be reduced by as much as 50 percent when the eGFR is &lt;10 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1">The initial dose of intermediate- or long-acting insulin in patients <strong>without</strong> CKD is approximately 10 units or 0.2 units/kg  (<a class="graphic graphic_algorithm graphicRef73793" href="/d/graphic/73793.html" rel="external">algorithm 2</a>). Thus, in a patient with an eGFR between 10 and 50 mL/min/1.73 m<sup>2</sup>, the initial dose would be approximately 7 units (75 percent of 10 units) once daily at bedtime.</p><p></p><p class="bulletIndent1">The balance between altered insulin resistance and insulin clearance as kidney dysfunction progresses is difficult to predict in any individual patient, so insulin adjustment is often largely empiric. Thus, it is important that blood glucose levels be monitored closely and that individually appropriate dose adjustments in insulin therapy be made. Continuous glucose monitoring (CGM) can be used to assist insulin adjustment treatment plans and mitigate the risk of hypoglycemia. (See <a class="local">'Daily glucose measurements'</a> above.)</p><p></p><p class="headingAnchor" id="H1917593936"><span class="h3">Patients on hemodialysis</span><span class="headingEndMark"> — </span>For most patients on hemodialysis, we use insulin rather than oral agents. KDIGO guidelines suggest that insulin, DPP-4 inhibitors, thiazolidinediones, sulfonylureas, or alpha-glucosidase inhibitors may be used for glycemic control in patients on hemodialysis  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>) [<a href="#rid14">14</a>]. There are few data evaluating the use of oral agents or GLP-1 receptor agonists in patients requiring dialysis [<a href="#rid37">37,47-49</a>].</p><p>The principles of insulin therapy are the same for patients on dialysis as for other patients with diabetes, and several different insulin regimens can be used  (<a class="graphic graphic_algorithm graphicRef73793" href="/d/graphic/73793.html" rel="external">algorithm 2</a>). For patients on hemodialysis, the initial dose of insulin should be decreased by approximately 50 percent, as described above for patients with nondialysis CKD and an eGFR &lt;10 mL/min/1.73 m<sup>2</sup>. The dose should be titrated upward, as indicated by blood glucose monitoring. Most patients will require more insulin than this initial dose. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>.)</p><p>A consensus approach does not exist to the choice of insulin in patients with diabetes and ESKD [<a href="#rid45">45</a>]. Some suggest that long-acting insulin preparations should be avoided, while others feel that such agents should be used.</p><p>Some clinicians prefer to use oral agents rather than insulin, especially among patients who are already on these agents and have achieved acceptable glycemic control. The preferred agents are <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> or <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> since they are primarily metabolized by the liver, inactive or only very weakly active metabolites are excreted in the urine, and the risk of hypoglycemia is lower than with other oral agents [<a href="#rid50">50</a>]. Although repaglinide drug concentration and elimination half-life are increased marginally in patients with a reduced glomerular filtration rate (GFR), dose reductions are not necessary and this agent may be an appropriate therapy for patients with ESKD [<a href="#rid51">51</a>]. DPP-4 inhibitors (eg, <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>, <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, <a class="drug drug_general" data-topicid="9534" href="/d/drug information/9534.html" rel="external">saxagliptin</a>) are an alternative option [<a href="#rid52">52</a>]. Saxagliptin should be administered after dialysis as it is removed by hemodialysis.</p><p class="headingAnchor" id="H1236122594"><span class="h3">Patients on peritoneal dialysis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of therapy</strong> – For patients who were already on an oral agent with good glycemic control prior to starting peritoneal dialysis, we typically continue the oral agent  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>). For patients who develop diabetes after starting peritoneal dialysis, we generally treat first with an oral agent. Our choice of agent is similar to what is described above for patients on hemodialysis (see <a class="local">'Patients on hemodialysis'</a> above). We prefer a sulfonylurea with a relatively lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> [initial dose 2.5 mg/day], <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a> [initial dose 1 mg/day], <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> [0.5 mg/day], or <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a> [5 mg once daily]). <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> should not be used among patients on peritoneal dialysis because of an increased risk of lactic acidosis [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">Over time, many patients will require insulin. The principles underlying subcutaneous insulin therapy are the same for patients with nondialysis CKD as for the general diabetic population (see  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>). The initial starting dose is similar to that for patients on hemodialysis (decrease the dose used in people without CKD by approximately 50 percent), with upward titration based upon blood glucose monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous versus intraperitoneal insulin</strong> – We and most other nephrologists prefer subcutaneous insulin for patients on continuous ambulatory peritoneal dialysis (CAPD) or continuous cycler peritoneal dialysis [<a href="#rid54">54</a>]. We do not use intraperitoneal insulin, as it often does not adequately control blood sugars. Even among patients who achieve adequate glycemic control with intraperitoneal insulin alone, the required insulin regimen is very complex since patients often alter CAPD schedules, as well as the timing of meals, necessitating constant adjustment of the intraperitoneal insulin, which is burdensome for the patient.</p><p></p><p class="bulletIndent1">Other disadvantages of intraperitoneal insulin include the risk of bacterial contamination of dialysate during injection of insulin into the bags [<a href="#rid55">55</a>], the requirement for a higher total insulin dose due to losses into spent dialysate and binding to the plastics in bags and tubing [<a href="#rid56">56-59</a>], and an associated risk of peritoneal fibroblastic proliferation [<a href="#rid60">60</a>] and, perhaps, of hepatic subcapsular steatosis [<a href="#rid56">56</a>]. Another potential concern is that the absorption of insulin may significantly vary among patients or may decline over time in a single individual due to acquired abnormalities in the peritoneal membrane [<a href="#rid61">61</a>]. One study of seven patients suggested that the latter is not a common problem, as there was no difference in insulin absorption after 30 months of CAPD [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">There are no long-term studies evaluating use of intraperitoneal insulin. A meta-analysis of three trials demonstrated better glycemic control, as assessed by glycated hemoglobin (A1C), with intraperitoneal compared with subcutaneous insulin in CAPD patients, but the insulin dose was more than double with intraperitoneal use [<a href="#rid63">63</a>]. Patients treated with intraperitoneal insulin had lower high-density lipoprotein cholesterol levels and higher triglyceride levels compared with those treated with subcutaneous insulin [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal or variations in peritoneal kinetics</strong> – The selection of oral agents described above assumes that peritoneal transfer kinetics are relatively normal. Patients treated with CAPD who have uncontrolled hyperglycemia should undergo a peritoneal equilibration test. (See  <a class="medical medical_review" href="/d/html/1972.html" rel="external">"Peritoneal equilibration test"</a>.)</p><p></p><p class="bulletIndent1">High transporters, who can have enormous glucose loads from rapid peritoneal glucose absorption  (<a class="graphic graphic_figure graphicRef65815" href="/d/graphic/65815.html" rel="external">figure 1</a>), will usually benefit from transfer to nocturnal automated peritoneal dialysis [<a href="#rid56">56,64</a>]. In addition to raising the blood glucose, the rapid glucose absorption lowers the osmotic gradient between dialysate and blood, resulting in reduced ultrafiltration, diminished urea removal, and fluid retention. A vicious cycle is then created, with generalized edema requiring frequent use of 2.5 and 4.25 percent dextrose dialysis solutions, leading to further hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbohydrate-sparing dialytic regimens</strong> – Adjusting the peritoneal dialysis solution may improve glycemic control in some patients. <a class="drug drug_general" data-topicid="8956" href="/d/drug information/8956.html" rel="external">Glucose polymers</a> were introduced to replace glucose-containing solutions by offering the possible advantages of decreased absorption of solute and increased ultrafiltration for a longer period of time. The use of a glucose polymer as an osmotic agent is particularly appealing as a substitute for glucose solutions, particularly in patients with diabetes [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/1905.html" rel="external">"Peritoneal dialysis solutions"</a>.)</p><p></p><p class="bulletIndent1">Carbohydrate-sparing dialytic regimens include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">Icodextrin</a>, in which carbohydrate absorption is equivalent to a 2.5 percent dextrose bag, but is associated with ultrafiltration of a 4.25 dextrose bag [<a href="#rid66">66</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Amino acid dialysate solutions, which are available in countries outside the United States</p><p></p><p class="headingAnchor" id="H4011614936"><span class="h3">Medications not recommended for hyperglycemia</span><span class="headingEndMark"> — </span>The following medications are not recommended for the treatment of hyperglycemia in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>.</p><p class="headingAnchor" id="H572628993"><span class="h4">Metformin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a>, which is a preferred agent in most patients, should not be used in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> because of an increased risk of lactic acidosis [<a href="#rid53">53</a>]. A discussion of eGFR thresholds for the safe use of metformin as well as dosing of metformin with mildly to moderately reduced eGFR is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Contraindications'</a> and  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Dosing'</a>.)</p><p class="headingAnchor" id="H2898770083"><span class="h4">SGLT2 inhibitors</span><span class="headingEndMark"> — </span>The sodium-glucose cotransporter 2 (SGLT2) inhibitors <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a>, <a class="drug drug_general" data-topicid="88901" href="/d/drug information/88901.html" rel="external">canagliflozin</a>, and <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> have demonstrated benefit for cardiorenal outcomes, especially for heart failure hospitalization and risk of kidney disease progression. However, for the treatment of hyperglycemia, SGLT2 inhibitors are not recommended for initiation in patients with an eGFR &lt;30 to 45 mL/min/1.73 m<sup>2</sup>, with some differences in each medication depending on the labeling. SGLT2 inhibitors have <strong>less glycemic efficacy </strong>in patients with an eGFR &lt;45 mL/min/1.73 m<sup>2</sup>, and in this setting, an additional agent may be necessary to achieve glycemic goals. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'</a>.)</p><p>Kidney and cardiac benefits have been shown in patients with an eGFR below this threshold. In the setting of declining eGFR, the main reason to prescribe SGLT2 inhibitors is to reduce progression of diabetic kidney disease; they should be prescribed at the lowest dose. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.) </p><p class="headingAnchor" id="H2807581032"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>Other medications that are infrequently used in patients with nondialysis CKD or ESKD include thiazolidinediones and alpha-glucosidase inhibitors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiazolidinediones </strong>(<a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a>) should be avoided in patients with advanced CKD, especially those with preexisting heart failure, given the risk of edema and heart failure.</p><p></p><p class="bulletIndent1">Thiazolidinediones enhance tissue sensitivity to insulin and suppress hepatic glucose production via binding to peroxisome proliferator-activated receptor (PPAR) gamma. (See  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">Pioglitazone</a>, the only drug of this class remaining on the market, is highly protein bound (primarily to albumin) and almost completely metabolized by the liver [<a href="#rid31">31,32,34</a>]. It has three active metabolites, but accumulation of the parent drug and major metabolites does not occur in the setting of CKD. Hemodialysis does not affect pioglitazone's pharmacokinetics.</p><p></p><p class="bulletIndent1">These agents are associated with heart failure and edema, which may be more frequent in patients also receiving insulin [<a href="#rid45">45</a>]. The mechanism of edema formation with these agents appears to be related to stimulation of PPAR gamma-mediated sodium reabsorption by renal epithelial sodium channels in the collecting duct [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-glucosidase</strong> <strong>inhibitors</strong>, such as <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> or <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a>, can be safely used in patients with stage 4 or 5 CKD [<a href="#rid14">14,68</a>]. In general, however, they are minimally effective in lowering glycated hemoglobin (A1C; mean 0.5 to 0.7 percent reduction) and are associated with limiting gastrointestinal side effects [<a href="#rid31">31-34</a>].</p><p></p><p class="bulletIndent1">These agents slow carbohydrate absorption from the gastrointestinal tract and reduce postprandial blood sugar peaks. (See  <a class="medical medical_review" href="/d/html/1787.html" rel="external">"Alpha-glucosidase inhibitors for treatment of diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a>, increased levels of the parent drug and metabolites are observed with CKD, but the clinical significance of this is not known. <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">Miglitol</a> is absorbed to a greater extent than acarbose and is largely excreted by the kidneys, with increased accumulation in patients with decreased kidney function. As with acarbose, the clinical significance of this is not known.</p><p></p><p class="headingAnchor" id="H88972370"><span class="h1">TROUBLESHOOTING</span><span class="headingEndMark"> — </span>Some patients with diabetes have persistent hyperglycemia, severe hyperglycemia, diabetic ketoacidosis, frequent hypoglycemia, or alternating episodes of hyperglycemia and hypoglycemia.</p><p class="headingAnchor" id="H4071369232"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>Inadequate insulin dose and noncompliance (with diet or the insulin regimen) are the most common causes of persistent hyperglycemia (defined as a A1C level &gt;9 percent) in patients on dialysis [<a href="#rid69">69</a>]. An additional problem is that microvascular disease can cause erratic absorption of insulin from the subcutaneous tissue, particularly if the patient does not rotate injection sites [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'Injection technique'</a>.)</p><p>The approach to these issues is the same for patients with chronic kidney disease (CKD) as for those without and is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'Determinants of insulin efficacy'</a> and  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Indications for a second agent'</a>.)</p><p class="headingAnchor" id="H4178742936"><span class="h2">Severe hyperglycemia and ketoacidosis</span><span class="headingEndMark"> — </span>Severe hyperglycemia, with serum glucose concentrations occasionally &gt;1000 mg/dL (55 mmol/L), may be observed among patients on dialysis. Unlike those without end-stage kidney disease (ESKD), however, hypovolemia and marked hypernatremia do not occur, since glucosuria is absent in anuric individuals. The net effect is minimal symptoms, even among those with extreme hyperglycemia [<a href="#rid70">70</a>].</p><p>However, these patients may have marked hyperkalemia due to potassium efflux from cells in response to extracellular fluid hypertonicity, as well as hyponatremia and acute intravascular volume expansion [<a href="#rid71">71</a>]. Patients with type 1 diabetes may also develop diabetic ketoacidosis.</p><p>Instead of fluid replacement, management is principally dependent upon the administration of low doses of intravenous insulin (commonly beginning at a dose of 2 units/hour) [<a href="#rid70">70</a>]. As with all patients with severe hyperglycemia and diabetic ketoacidosis, serum glucose and potassium concentrations must be closely monitored. (See  <a class="medical medical_review" href="/d/html/1795.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Monitoring'</a>.)</p><p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been associated with euglycemic ketoacidosis. This is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Diabetic ketoacidosis'</a>.)</p><p class="headingAnchor" id="H4018243597"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>Frequent or persistent hypoglycemia in patients on dialysis is often due to severe underdialysis, with poor calorie intake, or occult disease, such as infection or malignancy. Frequent adjustment of insulin dose and evaluation of blood glucose diaries or use of continuous glucose monitoring (CGM) are essential in this setting, as is provision of an adequate dialysis dose (see  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a> and  <a class="medical medical_review" href="/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a> and  <a class="medical medical_review" href="/d/html/1841.html" rel="external">"Protein intake in patients on maintenance hemodialysis"</a> and  <a class="medical medical_review" href="/d/html/1850.html" rel="external">"Assessment of nutritional status in patients on hemodialysis"</a>). Drugs that interfere with the counterregulatory response to hypoglycemia (such as beta blockers) and long-acting insulin and oral agents should be discontinued, if possible, until more stable glycemic control without hypoglycemia is achieved.</p><p class="headingAnchor" id="H762955790"><span class="h2">Alternating hypoglycemia and hyperglycemia</span><span class="headingEndMark"> — </span>Patients with ESKD and diabetes often have gastroparesis [<a href="#rid57">57</a>], which complicates the timing of insulin injections as well as oral agents that are taken in relation to food intake. Gastric emptying studies will confirm the diagnosis, which can often be effectively treated with <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> or <a class="drug drug_general" data-topicid="9153" href="/d/drug information/9153.html" rel="external">bethanechol</a> [<a href="#rid57">57</a>]. Improvement in glycemic control may also improve gastric motility. (See  <a class="medical medical_review" href="/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Gastroparesis'</a>.)</p><p>Other causes of brittle blood glucose include patient misunderstanding of the timing of insulin injections, poor compliance with dietary restrictions and insulin therapy, erratic eating habits, and poor timing of continuous ambulatory peritoneal dialysis (CAPD) exchanges. These problems can often be corrected with patient re-education. Poor adherence, impaired vision, and a depressive illness should also be sought. (See  <a class="medical medical_review" href="/d/html/1803.html" rel="external">"Approach to the adult with brittle diabetes or high glucose variability"</a>.)</p><p class="headingAnchor" id="H114027059"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H15753507"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Chronic kidney disease (CKD) is associated with insulin resistance, and in patients with diabetes, glycemic control may deteriorate as kidney function declines. In advanced CKD, however, there is a marked reduction in insulin clearance, leading to a decrease in insulin requirement or even the cessation of insulin therapy in patients with type 2 diabetes. Careful, individualized therapy is essential among patients with advanced CKD or end-stage kidney disease (ESKD). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring glycemia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We assess chronic glycemic control in patients with diabetes and predialysis CKD or ESKD with glycated hemoglobin (A1C) as we do in patients with diabetes and normal kidney function. It is important to be aware of the specific assay used in each dialysis facility and the extent to which kidney disease and other factors affect the relationship of A1C levels and average glycemia. (See <a class="local">'Chronic glycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurements of instantaneous glucose levels (self-monitoring of blood glucose [with fingersticks and a glucose meter] and real-time continuous glucose monitoring [CGM]) are used to manage diabetes from hour-to-hour and day-to-day, to aid in dose selection in insulin-treated patients, and for safety. CGM may be useful to support treatment decisions for individual patients who have A1C values discordant with self-monitored blood glucose measures or clinical symptoms, or when initiating new anti-hyperglycemic therapy or adjusting current medications to ensure achievement of glycemic targets and avoidance of hypoglycemia. (See <a class="local">'Daily glucose measurements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic targets</strong> – Target A1C levels should be tailored to the individuals, based upon patient factors, such as risk of hypoglycemia, presence of cardiovascular disease, and life expectancy. A1C targets generally range from &lt;6.5 to &lt;8 percent. (See <a class="local">'Glycemic targets'</a> above and  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General management</strong> – All patients with diabetes should participate in a comprehensive diabetes self-management education program, which includes individualized instruction on nutrition, physical activity, optimizing metabolic control, and preventing complications. Pharmacologic therapies for the treatment of hyperglycemia include oral agents, noninsulin injectable agents, and insulin. (See <a class="local">'General management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic therapy</strong> – Pharmacologic therapies for the treatment of hyperglycemia include oral agents, noninsulin injectable agents, and insulin. Our approach, which is largely in agreement with guidelines from the American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO), is as follows  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients not on dialysis</strong> – For patient with stage 4 CKD, we suggest a glucagon-like peptide 1 (GLP-1) receptor agonist rather than another agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The GLP-1 receptor agonists <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>, <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a>, and <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a> have kidney and cardiovascular protective benefits as well as documented safety in patients with an estimated glomerular filtration rate (eGFR) &gt;15 mL/min/1.73 m<sup>2</sup>. Sulfonylureas with the lowest risk of hypoglycemia (<a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, or <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a> [not available in the United States], <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a>, or <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>) are alternatives.</p><p></p><p class="bulletIndent3">For patients with CKD stage 5 who are not on dialysis, we suggest a sulfonylurea with inactive metabolites and a relatively lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, or <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a> [not available in the United States]) rather than another agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">Repaglinide</a>, <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, or cautious use of a GLP-1 receptor agonist are alternatives to sulfonylureas with inactive metabolites.</p><p></p><p class="bulletIndent3">Patients who are unable to achieve their glycemic target with oral agents or a GLP-1 receptor agonist are treated with insulin. (See <a class="local">'Patients not on dialysis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients on hemodialysis</strong> – For most patients on hemodialysis, we suggest using insulin rather than oral agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Several different insulin regimens can be used  (<a class="graphic graphic_algorithm graphicRef73793" href="/d/graphic/73793.html" rel="external">algorithm 2</a>). The initial dose of insulin should be decreased by approximately 50 percent.</p><p></p><p class="bulletIndent3">However, some clinicians prefer to use oral agents rather than insulin, especially among patients who have already achieved acceptable glycemic control on these agents. (See <a class="local">'Patients on hemodialysis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients on peritoneal dialysis</strong> – For patients on peritoneal dialysis who are already on an oral agent with good glycemic control prior to starting peritoneal dialysis and for patients who develop diabetes after starting dialysis, we suggest using an oral agent rather than insulin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The preferred agents and suggested initial doses include <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> (2.5 mg/day), <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a> (1 mg/day), <a class="drug drug_general" data-topicid="9604" href="/d/drug information/9604.html" rel="external">repaglinide</a> (0.5 mg/day), or <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a> (5 mg once daily).</p><p></p><p class="bulletIndent3">Many patients on peritoneal dialysis will require insulin therapy to achieve adequate glycemic control. For such patients, we suggest the use of subcutaneous, rather than intraperitoneal, insulin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The initial dose of insulin should be approximately 50 percent of the dose used in people without CKD. (see <a class="local">'Patients on peritoneal dialysis'</a> above).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> and sodium-glucose cotransporter 2 (SGLT2) inhibitors should not be used for the treatment of hyperglycemia in patients with advanced CKD or ESKD. In the setting of declining eGFR, SGLT2 inhibitors are often prescribed to reduce progression of diabetic kidney disease. (See <a class="local">'Medications not recommended for hyperglycemia'</a> above and  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Type 2 diabetes: Treat with additional kidney-protective therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Troubleshooting</strong> – Severe hyperglycemia may be observed among patients on dialysis with diabetes. Unlike those without ESKD, hypovolemia and marked hypernatremia do not occur, since glucosuria is absent in anuric individuals. Patients have few symptoms but may have marked hyperkalemia, hyponatremia, and acute intravascular volume expansion. Instead of fluid replacement, management is principally dependent upon the administration of low doses of intravenous insulin. (See <a class="local">'Troubleshooting'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lo C, Lui M, Ranasinha S, et al. Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. Diabetes Res Clin Pract 2014; 104:84.</a></li><li><a class="nounderline abstract_t">Little RR, Rohlfing CL, Tennill AL, et al. Measurement of Hba(1C) in patients with chronic renal failure. Clin Chim Acta 2013; 418:73.</a></li><li><a class="nounderline abstract_t">Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73:1062.</a></li><li><a class="nounderline abstract_t">Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6:1635.</a></li><li><a class="nounderline abstract_t">Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010; 31:375.</a></li><li><a class="nounderline abstract_t">Dozio E, Corradi V, Proglio M, et al. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res Clin Pract 2018; 140:9.</a></li><li><a class="nounderline abstract_t">Konya J, Ng JM, Cox H, et al. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment. Diabet Med 2013; 30:1250.</a></li><li><a class="nounderline abstract_t">Chen CW, Drechsler C, Suntharalingam P, et al. High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on Hemodialysis. Clin Chem 2017; 63:477.</a></li><li><a class="nounderline abstract_t">Selvin E, Rawlings AM, Grams M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2014; 2:279.</a></li><li><a class="nounderline abstract_t">Nathan DM, McGee P, Steffes MW, et al. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014; 63:282.</a></li><li><a class="nounderline abstract_t">Joubert M, Fourmy C, Henri P, et al. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract 2015; 107:348.</a></li><li><a class="nounderline abstract_t">Sloand JA. Dialysis patient safety: safeguards to prevent iatrogenic hypoglycemia in patients receiving icodextrin. Am J Kidney Dis 2012; 60:514.</a></li><li class="breakAll">http://www.pharmacypracticenews.com/download/BGSystems.pdf (Accessed on May 28, 2015).</li><li class="breakAll">https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf (Accessed on November 20, 2020).</li><li><a class="nounderline abstract_t">de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45:3075.</a></li><li><a class="nounderline abstract_t">Tzamaloukas AH, Murata GH, Zager PG, et al. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J 1993; 39:880.</a></li><li><a class="nounderline abstract_t">McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40:566.</a></li><li><a class="nounderline abstract_t">Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29:1496.</a></li><li><a class="nounderline abstract_t">Williams ME, Lacson E Jr, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006; 70:1503.</a></li><li><a class="nounderline abstract_t">Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010; 55:875.</a></li><li><a class="nounderline abstract_t">Williams ME, Lacson E Jr, Wang W, et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5:1595.</a></li><li><a class="nounderline abstract_t">Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial 2010; 23:148.</a></li><li><a class="nounderline abstract_t">Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011; 6:1041.</a></li><li><a class="nounderline abstract_t">Hill CJ, Maxwell AP, Cardwell CR, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis 2014; 63:84.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S158.</a></li><li><a class="nounderline abstract_t">Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839.</a></li><li><a class="nounderline abstract_t">Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375:1834.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121.</a></li><li><a class="nounderline abstract_t">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605.</a></li><li><a class="nounderline abstract_t">Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013; 9:147.</a></li><li><a class="nounderline abstract_t">Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011; 12:57.</a></li><li><a class="nounderline abstract_t">Di Lullo L, Mangano M, Ronco C, et al. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes Metab Syndr 2017; 11 Suppl 1:S295.</a></li><li><a class="nounderline abstract_t">Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015; 87:308.</a></li><li><a class="nounderline abstract_t">Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet 2018; 57:1571.</a></li><li><a class="nounderline abstract_t">Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. Clin Pharmacokinet 2017; 56:1381.</a></li><li><a class="nounderline abstract_t">Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018; 9:CD011798.</a></li><li><a class="nounderline abstract_t">Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 2015; 54:1.</a></li><li><a class="nounderline abstract_t">Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev 2016; 32:776.</a></li><li><a class="nounderline abstract_t">Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36:1067.</a></li><li><a class="nounderline abstract_t">Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab 2013; 4:95.</a></li><li><a class="nounderline abstract_t">McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36:237.</a></li><li><a class="nounderline abstract_t">Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28:55.</a></li><li><a class="nounderline abstract_t">Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26 Suppl 4:73.</a></li><li><a class="nounderline abstract_t">Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17:365.</a></li><li class="breakAll">Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 4th ed, American College of Physicians, Philadelphia 1999.</li><li><a class="nounderline abstract_t">Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013; 61:579.</a></li><li><a class="nounderline abstract_t">Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65:1230.</a></li><li><a class="nounderline abstract_t">Idorn T, Knop FK, Jørgensen MB, et al. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care 2016; 39:206.</a></li><li class="breakAll">Tzamaloukas AH, Friedman EA. Diabetes. In: Handbook of Dialysis, 3rd ed, Daugirdas JT, Blake PG, Ing TS (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2001. p.453.</li><li><a class="nounderline abstract_t">Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886.</a></li><li><a class="nounderline abstract_t">Park SH, Nam JY, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore) 2016; 95:e4543.</a></li><li><a class="nounderline abstract_t">Garg R, Williams ME. Diabetes management in the kidney patient. Med Clin North Am 2013; 97:135.</a></li><li><a class="nounderline abstract_t">Wijewickrama P, Williams J, Bain S, et al. Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis. Kidney Int Rep 2023; 8:700.</a></li><li><a class="nounderline abstract_t">Selgas R, Diez JJ, Muñoz J, et al. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv Perit Dial 1989; 5:181.</a></li><li><a class="nounderline abstract_t">Diaz-Buxo JA. Blood glucose control in diabetics: I. Semin Dial 1993; 6:392.</a></li><li><a class="nounderline abstract_t">Daniels ID, Markell MS. Blood glucose control in diabetics: II. Semin Dial 1993; 6:394.</a></li><li><a class="nounderline abstract_t">Maxwell DR, Prince MJ. Blood glucose control in diabetics: III. Semin Dial 1993; 6:397.</a></li><li><a class="nounderline abstract_t">Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002; 13 Suppl 1:S92.</a></li><li class="breakAll">Selgas R, Lopez-Riva A, Alvaro F, et al. Insulin influence on the mitogenic-induced effect of the peritoneal effluent in CAPD patients. In: Adv Peritoneal Dial, Khanna R, Nolph KD, Prowant B, et al (Eds), University of Toronto Press, Toronto 1991. Vol 7, p.161.</li><li><a class="nounderline abstract_t">Fine A, Parry D, Ariano R, Dent W. Marked variation in peritoneal insulin absorption in peritoneal dialysis. Perit Dial Int 2000; 20:652.</a></li><li><a class="nounderline abstract_t">Scavini M, Pincelli A, Petrella G, et al. Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy. Diabetes Care 1995; 18:56.</a></li><li><a class="nounderline abstract_t">Almalki MH, Altuwaijri MA, Almehthel MS, et al. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Invest Med 2012; 35:E132.</a></li><li><a class="nounderline abstract_t">Twardowski ZJ, Nolph KD, Khanna R, et al. Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. ASAIO Trans 1986; 32:575.</a></li><li><a class="nounderline abstract_t">Holmes C, Mujais S. Glucose sparing in peritoneal dialysis: implications and metrics. Kidney Int Suppl 2006; :S104.</a></li><li><a class="nounderline abstract_t">Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial 2004; 17:498.</a></li><li><a class="nounderline abstract_t">Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861.</a></li><li><a class="nounderline abstract_t">Lin WH, Yang CY, Kuo S, et al. Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study. Diabetes Res Clin Pract 2021; 172:108489.</a></li><li><a class="nounderline abstract_t">Tzamaloukas AH, Murata GH, Eisenberg B, et al. Hypoglycemia in diabetics on dialysis with poor glycemic control: hemodialysis versus continuous ambulatory peritoneal dialysis. Int J Artif Organs 1992; 15:390.</a></li><li><a class="nounderline abstract_t">Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13:4.</a></li><li><a class="nounderline abstract_t">Montoliu J, Revert L. Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure. Am J Kidney Dis 1985; 5:47.</a></li></ol></div><div id="topicVersionRevision">Topic 1857 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24573088" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318566" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Measurement of Hba(1C) in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18288102" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597024" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299782" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596954" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758176" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737895" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703046" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23990364" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638452" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835903" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dialysis patient safety: safeguards to prevent iatrogenic hypoglycemia in patients receiving icodextrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835903" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Dialysis patient safety: safeguards to prevent iatrogenic hypoglycemia in patients receiving icodextrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835903" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dialysis patient safety: safeguards to prevent iatrogenic hypoglycemia in patients receiving icodextrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36189689" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123921" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The relationship between glycemic control and morbidity and mortality for diabetics on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200809" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diabetes education and care management significantly improve patient outcomes in the dialysis unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801568" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941022" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346561" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671217" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374552" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glycemic control and burnt-out diabetes in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511838" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958400" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078590" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854085" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Liraglutide and Renal Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27633186" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27295427" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29910024" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358424" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Noninsulin glucose-lowering agents for the treatment of patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21303332" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292575" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599253" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Metformin and other antidiabetic agents in renal failure patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29623579" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28349386" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246878" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25331711" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102969" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248197" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23730503" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033241" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490580" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10922977" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Management of drugs affecting blood glucose in diabetic patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461745" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461745" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352379" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21977965" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283739" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283739" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610054" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27512877" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290735" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diabetes management in the kidney patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37069983" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2577407" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Blood glucose control in diabetics: I</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Blood glucose control in diabetics: II</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Blood glucose control in diabetics: III</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792768" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792768" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216554" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Marked variation in peritoneal insulin absorption in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698048" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22673316" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3778773" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080098" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Glucose sparing in peritoneal dialysis: implications and metrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660581" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Metabolic consequences of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007095" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33035600" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516987" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hypoglycemia in diabetics on dialysis with poor glycemic control: hemodialysis versus continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10740665" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impact of end-stage renal disease and dialysis on glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966469" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
